Abstract Dose selection and confirmation are critical tasks in the development of therapeutic antibodies. These tasks could become particularly challenging in the absence of robust pharmacodynamics biomarkers or at very flat dose-response curves. Although much knowledge has been acquired in the past decade, it remains uncertain which factors are relevant and how to select doses more rationally. In this study, we developed a quantitative metric, Therapeutic Exposure Affinity Ratio (TEAR), to retrospectively evaluate up to 60 approved antibodies and their therapeutic doses (TDs), and systematically assessed the factors that are relevant to antibody TDs and dose selection patterns. This metric supported us to analyze many factors that are beyond antibody pharmacokinetics and target binding affinity. Our results challenged the traditional perceptions about the importance of target turnovers and target anatomical locations in the selection of TDs, highlighted the relevance of an overlooked factor, antibody mechanisms of action. Overall, this study provided insights into antibody dose selection and confirmation in the development of therapeutic antibodies.

Quantitatively Modeling Factors that Influence the Therapeutic Doses of Antibodies